INSM hanging in there. FYI found this note by Lazard
Insmed "buy"
Monday, February 19, 2007 4:07:30 AM ET
Lazard Capital Markets
NEW YORK, February 19 (newratings.com) - Analysts at Lazard Capital maintain their "buy" rating on Insmed Inc (ticker: INSM). The target price is set to $3.
In a research note published on February 16, the analysts mention that as a result of stipulation submitted to the court by Insmed and Tercica, the preliminary injunction hearing has been delayed. The reasons for the delay in the hearing and when it would be scheduled appear uncertain, the analysts say.
Recommend this article to a friend
INSM.NAS | detailed quote - chart - all headlines - add to watchlist
News 
Market Data 
Discover 
AI
